Determination of safety is the most important goal of this first study with C326. Other goals of the study are to examine:~pharmacokinetics (change in serum concentrations over time),~biological activity (change in blood markers relecting activity of Crohn's Disease),~effects on symptoms of Crohn's disease.~Participants may receive either a single or several intravenous infusions of C326 or matching placebo.
The purpose of this study is to determine whether C326, a new inhibitor of IL-6, is safe in patients with Crohn's disease.